modelD07AB09
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Triamcinolone | |
| ATC code: | D07AB09 | route: | topical |
| compartments: | 1 | |
| dosage: | 15 | mg |
| volume of distribution: | 1.5 | L |
| clearance: | 5 | L/h |
| other parameters in model implementation | ||
Triamcinolone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. It is used for the treatment of various dermatological disorders, allergic conditions, and, depending on the formulation, for intra-articular and intramuscular administration. Triamcinolone is approved for clinical use and is available in several formulations including topical, injectable, and inhaled forms.
Pharmacokinetics
Pharmacokinetic parameters estimated for topical dermatological use in adults, based on general corticosteroid properties due to lack of published primary pharmacokinetic data for topical triamcinolone (ATC D07AB09).
References
Ramadas, AA, et al., & Kumar, SP (2016). Systemic absorption of 0.1% triamcinolone acetonide as topical application in management of oral lichen planus. Indian journal of dental research : official publication of Indian Society for Dental Research 27(3) 230–235. DOI:10.4103/0970-9290.186237 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27411649
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)